Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed

Singapore Deputy PM stresses preparation for next pandemic

Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.

Triomphe
Thomas Triomphe, executive VP, head of vaccines, Sanofi • Source: Sanofi

Sanofi is betting big on cutting-edge manufacturing and digital technologies as it broadens its vaccines innovation pipeline and gears alongside to ensure agility and flexibility in responding to the risk of future pandemics.

At the fulcrum of this new push are two Evolutive Vaccine Facilities (EVF), one in Neuville sur Saône, France, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip